MEDI 1873

Drug Profile

MEDI 1873

Alternative Names: GITR-agonist-fusion-protein; GITR-protein-stimulants; MEDI1873; Tumour-necrosis-factor-receptor-superfamily-member-18-protein-stimulants

Latest Information Update: 27 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Antineoplastics
  • Mechanism of Action TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacdynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Nov 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV)
  • 29 Oct 2015 Preclinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top